NDMM patients with thrombocytopenia presented a larger number of bone marrow plasma cells (p < 0.001), more advanced Durie‐Salmon (DS) stage (more severe anemia and hypercalcemia, p < 0.001), ISS stage [lower albumin and higher β2‐microglobulin (β2‐MG) levels, p < 0.001] and revised ISS (R‐ISS) stage [higher lactate dehydrogenase (LDH) levels and more patients with HRCA, p < 0.001] than patients with a normal platelet count (Table 1). This evidence concerns the gene HLA-G and hypercalcemia disease.